Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome

[1]  A. Hofman,et al.  A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly , 2014, Molecular Psychiatry.

[2]  Matthew Schreiber,et al.  Alzheimer’s Disease Genetics , 2014, Current Behavioral Neuroscience Reports.

[3]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[4]  D. Harold,et al.  Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome , 2013, Neurobiology of Aging.

[5]  Jason J. Corneveaux,et al.  Genetic susceptibility for Alzheimer disease neuritic plaque pathology. , 2013, JAMA neurology.

[6]  David A. Bennett,et al.  The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers , 2013, PLoS genetics.

[7]  Mark T. W. Ebbert,et al.  Genetics of Alzheimer's Disease , 2013, BioMed research international.

[8]  A. Attie,et al.  Protein Sorting Motifs in the Cytoplasmic Tail of SorCS1 Control Generation of Alzheimer's Amyloid-β Peptide , 2013, The Journal of Neuroscience.

[9]  J. Trojanowski,et al.  Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker , 2013, Alzheimer's Research & Therapy.

[10]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[11]  G. Kirov,et al.  A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk , 2012, Human molecular genetics.

[12]  Lawrence Rajendran,et al.  Role of genes linked to sporadic Alzheimer’s disease risk in the production of β-amyloid peptides , 2012, Proceedings of the National Academy of Sciences.

[13]  L. Farrer,et al.  Identification of Alzheimer disease-associated variants in genes that regulate retromer function , 2012, Neurobiology of Aging.

[14]  A. Janssens,et al.  Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome , 2012, Neurobiology of Aging.

[15]  W. Silverman,et al.  Aging and Down Syndrome , 2012, Current gerontology and geriatrics research.

[16]  John Hardy,et al.  The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE , 2012, Neurobiology of Aging.

[17]  R. Mayeux,et al.  Association between variants in IDE-KIF11-HHEX and plasma amyloid β levels , 2012, Neurobiology of Aging.

[18]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[19]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[20]  Sandro Sorbi,et al.  Meta-analysis of the association between variants in SORL1 and Alzheimer disease. , 2011, Archives of neurology.

[21]  M. A. Kelly,et al.  Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome , 2011, Neuroscience Letters.

[22]  J. Haines,et al.  SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk , 2011, Annals of neurology.

[23]  K. Lunetta,et al.  Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. , 2010, Archives of neurology.

[24]  S. Potkin,et al.  Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.

[25]  R. Mayeux,et al.  Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome , 2010, Neurology.

[26]  K. Jellinger,et al.  Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[27]  Rudolph E Tanzi,et al.  Diabetes-Associated SorCS1 Regulates Alzheimer's Amyloid-β Metabolism: Evidence for Involvement of SorL1 and the Retromer Complex , 2010, The Journal of Neuroscience.

[28]  V. Pankratz,et al.  Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aß, and Alzheimer's Disease , 2010, PloS one.

[29]  C. Ferrarese,et al.  Increased Soluble APPα, Abeta 1-42, and Anti-Abeta 1-42 Antibodies in Plasma From Down Syndrome Patients , 2010, Alzheimer disease and associated disorders.

[30]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[31]  M. Schulze,et al.  Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes , 2009, Journal of Molecular Medicine.

[32]  M. Sano,et al.  The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down Syndrome , 2009, Alzheimer disease and associated disorders.

[33]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[34]  L. Buée,et al.  Association of plasma amyloid β with risk of dementia , 2009, Neurology.

[35]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[36]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[37]  J. Haines,et al.  CALHM1 Polymorphism is not Associated with Late‐onset Alzheimer Disease , 2009, Annals of human genetics.

[38]  S. DeKosky,et al.  No association between CALHM1 variation and risk of Alzheimer disease , 2009, Human mutation.

[39]  C. Ballard,et al.  Amyloid β concentrations in older people with Down syndrome and dementia , 2009, Neuroscience Letters.

[40]  J. Jia,et al.  Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease , 2009, Brain Research.

[41]  D. Blacker,et al.  No Association between CALHM1 and Alzheimer's Disease Risk , 2008, Cell.

[42]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[43]  F. Pasquier,et al.  A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Aβ Levels, and Alzheimer's Disease Risk , 2008, Cell.

[44]  J. Jia,et al.  Down‐regulation of insulin‐degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42 , 2008, The European journal of neuroscience.

[45]  J. H. Kim,et al.  Association of polymorphisms in the insulin-degrading enzyme gene with type 2 diabetes in the Korean population. , 2008, Diabetes research and clinical practice.

[46]  N. Schupf,et al.  Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome , 2007, Neuroscience Letters.

[47]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[48]  R. Mayeux,et al.  Elevated plasma amyloid β-peptide Aβ42, incident dementia and mortality in Down syndrome , 2007 .

[49]  W. Markesbery,et al.  Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. , 2007, Archives of neurology.

[50]  B. Yandell,et al.  SORCS1: A Novel Human Type 2 Diabetes Susceptibility Gene Suggested by the Mouse , 2007, Diabetes.

[51]  J. Buxbaum,et al.  Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease , 2007, Neurobiology of Aging.

[52]  H. Soininen,et al.  Insulin-degrading enzyme is genetically associated with Alzheimer’s disease in the Finnish population , 2007, Journal of Medical Genetics.

[53]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[54]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[55]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[56]  E. Head,et al.  Beta-amyloid, oxidative stress and down syndrome. , 2006, Current Alzheimer research.

[57]  S. DeKosky,et al.  Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease , 2006, Neuroscience Letters.

[58]  Philipp W. Raess,et al.  Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus , 2006, Nature Genetics.

[59]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[60]  M. Folstein,et al.  Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.

[61]  J. Sidtis,et al.  Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[62]  Taylor J. Maxwell,et al.  Association studies between risk for late‐onset Alzheimer's disease and variants in insulin degrading enzyme , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[63]  R. Mayeux,et al.  Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.

[64]  C. Morris,et al.  Influence of the amyloid precursor protein locus on dementia in Down syndrome , 2004, Neurology.

[65]  N. Schupf,et al.  Dementia in adults with mental retardation: assessment at a single point in time. , 2004, American journal of mental retardation : AJMR.

[66]  Mitsutoshi Yamamoto,et al.  No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[67]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[68]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[69]  P. Wilson,et al.  Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. , 2003, Diabetes.

[70]  M. McCarthy,et al.  Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility. , 2003, Diabetes.

[71]  D. Campion,et al.  Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease , 2002, Neuroscience Letters.

[72]  M. Owen,et al.  Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease , 2001, Human Genetics.

[73]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[74]  E. Head,et al.  Down syndrome and Alzheimer's disease: a link between development and aging. , 2001, Mental retardation and developmental disabilities research reviews.

[75]  B. Tycko,et al.  Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome , 2001, Neuroscience Letters.

[76]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[77]  H. Luthman,et al.  Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. , 2000, Human molecular genetics.

[78]  E. Aylward,et al.  Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability. , 2000, Journal of intellectual disability research : JIDR.

[79]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[80]  H. Wiśniewski,et al.  Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .

[81]  B. Bogerts,et al.  Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques , 1999, Neuroscience Letters.

[82]  H. Wiśniewski,et al.  Increased plasma amyloid β protein 1–42 levels in Down syndrome , 1998, Neuroscience Letters.

[83]  E. Aylward,et al.  Diagnosis of dementia in individuals with intellectual disability. , 1997, Journal of intellectual disability research : JIDR.

[84]  T. Tokuda,et al.  Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome , 1997 .

[85]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[86]  Brian J Cummings,et al.  Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity , 1995, The Lancet.

[87]  D. Price,et al.  Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. , 1995, The American journal of pathology.

[88]  I. Kurochkin,et al.  Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme , 1994, FEBS letters.

[89]  V. Prasher,et al.  Down's syndrome, dementia, and superoxide dismutase , 1993, British Journal of Psychiatry.

[90]  G. Reynolds,et al.  Free radical damage in Down's syndrome brain. , 1993, Biochemical Society transactions.

[91]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[92]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[93]  Z. Walker,et al.  Oxidative stress and memory decline in adults with Down syndrome: longitudinal study. , 2012, Journal of Alzheimer's disease : JAD.

[94]  F. Schmitt,et al.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. , 2011, Journal of Alzheimer's disease : JAD.

[95]  G. H. Sergievsky.  Type 2 Diabetes and Late-Onset Alzheimer ’ s Disease , 2011 .

[96]  A. Ruiz,et al.  CALHM1 P86L polymorphism is associated with late-onset Alzheimer's disease in a recessive model. , 2010, Journal of Alzheimer's disease : JAD.

[97]  P. Bosco,et al.  The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. , 2010, Journal of Alzheimer's disease : JAD.

[98]  S. Love,et al.  ACE variants and association with brain Aβ levels in Alzheimer's disease. , 2010, American journal of translational research.

[99]  P. D. de Bakker.  Selection and evaluation of Tag-SNPs using Tagger and HapMap. , 2009, Cold Spring Harbor protocols.

[100]  T. Uema,et al.  The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. , 2007, Human molecular genetics.

[101]  R. Mayeux,et al.  Incident Dementia, and Mortality in Down Syndrome , 2007 .

[102]  M. McCarthy,et al.  High-density haplotype structure and association testing of the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206 people. , 2006, Diabetes.

[103]  BMC Endocrine Disorders BioMed Central , 2005 .

[104]  G. Schellenberg,et al.  Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-ε4 Allele , 2003 .

[105]  K. Kovacina,et al.  Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. , 2003, The American journal of pathology.

[106]  L S Honig,et al.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.

[107]  S A Small,et al.  Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. , 1999, Annals of neurology.

[108]  H. Wiśniewski,et al.  Increased plasma amyloid beta protein 1-42 levels in Down syndrome. , 1998, Neuroscience letters.

[109]  S. Younkin,et al.  The APP and PS1/2 Mutations Linked to Early Onset Familial Alzheimer’s Disease Increase the Extracellular Concentration of Aβ1–42(43) , 1998 .

[110]  T. Tokuda,et al.  Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. , 1997, Annals of neurology.

[111]  S. Younkin.  [The AAP and PS1/2 mutations linked to early onset familial Alzheimer's disease increase the extracellular concentration and A beta 1-42 (43)]. , 1997, Rinsho shinkeigaku = Clinical neurology.

[112]  D. Mann,et al.  Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome , 1996, Nature Medicine.

[113]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[114]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .